… scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation
EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the …

… EGFR TKIs is around 9–12 months in EGFR-mutant NSCLC patients. The acquired resistance
to EGFR TKIs including third-generation EGFR TKI … NSCLC and oncogenic EGFR pathway …

… EGFR TKIs improve response rates, time to progression, and overall survival. … EGFR mutant
lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. …

… in nonsmoking patients with non-small cell lung cancer (NSCLC). However, this does not …
for EGFR mutations. Our case–control study revealed that lung cancers harbouring EGFR …

… factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) – … with EGFR mutation-positive
non-small cell lung cancer (NSCLC). Given the long-term exposure of such patients to EGFR-TKIs, …

… of all cancer deaths worldwide. Non-small cell lung cancer (NSCLC) constitutes over 80%
of lung cancer … to combat lung cancer. The development of epidermal growth factor receptor (…

… EGFR tertiary mutations are common resistance mechanisms … EGFR-TKIs in lung cancer,
and multiple EGFR tertiary mutations have been observed. The C797S mutation at EGFR exon …

… Mutation at the TK domain of EGFR results … lung cancers harboring constitutively active
mutant EGFR are exquisitely sensitive to the apoptotic or growth inhibitory activities of EGFR TKIs …

… –small cell lung cancer harboring activating mutations of the EGFR gene. We examined the
effects of EGFR tyrosine kinase inhibitor (TKI) therapy in such patients on the tumor immune …

… patients with EGFR-mutant lung cancer and acquired resistance to EGFR-TKI therapies that
… Our findings indicate that second-site EGFR T790M mutations are the dominant mechanism …